The combined anti-inflammatory and bronchodilating properties of
leukotriene modifiers described by Salvi and colleagues1
highlight both the early (step 2) role for these controller agents as
well as a role in all stages of severity of persistent asthma.
Leukotriene modifiers, particularly in perimenstrual-, exercise-, and
aspirin-triggered asthma and asthma with comorbid rhinitis, merit
consideration as an addition to inhaled steroid therapy as a controller
targeting inflammation not adequately controlled by steroids.